Paul de Potocki, CEO of Oncozenges, does not rule out the possibility of resuming the company’s paused drug development, according to his statement to Di. However, in order for this to happen, the company needs a substantial investment of 60 million SEK, which exceeds its current market value of a mere 44 million SEK.
“Oncozenge-vd’s Focus: Seeking New Funding or a New Home”
